# C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity.

- **DOI:** [10.1038/s41467-017-02729-0](https://doi.org/10.1038/s41467-017-02729-0)
- **Rating:** Sound (3.1 out of 5)
- **Verdict:** Three isogenic patient-line comparisons link C9ORF72 expansion to altered AMPA receptors and excitotoxic vulnerability, but do not isolate GluA1-specific causation.
- **Framework version:** v5.13
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-16
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41467-017-02729-0

## Key claims

1. increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.
   - Support: Tentative
   - Type: Primary finding
   - Basis: GluA1-specific causation is not isolated by receptor-blocking pharmacology or the edited-line comparisons
   - Location: Abstract
2. mutant C9ORF72 cortical neurons possess predominantly Ca2+-impermeable AMPARs, indicating that mutant C9ORF72-dependent increases in Ca2+-permeable AMPARs are selective to MNs.
   - Support: Tentative
   - Type: Secondary
   - Basis: the cortical comparison uses one patient line and does not test cortical excitotoxic vulnerability
   - Location: Discussion
3. [Excitotoxicity vulnerability] is abolished by CRISPR/Cas9-mediated correction of the C9ORF72 repeat expansion in MNs.
   - Support: Supported
   - Type: Secondary
   - Basis: rescue across three patient-line pairs is constrained by one selected clone per line and concurrent wild-type allele editing
   - Location: Introduction
4. AMPAR expression is also selectively dysregulated in spinal cord, but not cortical, post-mortem tissue from patients harboring C9ORF72 repeat expansions.
   - Support: Supported
   - Type: Secondary
   - Basis: patient-level tissue measurements support the regional association in only three patients and three controls
   - Location: Introduction, paragraph 3

## Strengths

- **Repeat correction tested across three patient lines** Three patient-derived lines each have an edited counterpart, linking repeat excision to reversal of the expression and receptor-function phenotypes.
  - Dimension: methodological rigour
  - Location: Figures 1, 5–6
- **Convergent assays extend the excitotoxicity mechanism** RNA measurements, protein measurements, receptor physiology, and antagonist-sensitive cell death connect the C9ORF72 phenotype to persistent Ca2+-permeable AMPAR function.
  - Dimension: contribution
  - Location: Figures 4–6
- **Alternative mechanisms receive substantive interpretive attention** The Discussion addresses intact GluA2 editing, differences between neuron-only and mixed cultures, and possible contributions from PICK1-dependent receptor trafficking.
  - Dimension: positioning
  - Location: Figure 5d; Discussion

## Limitations

- **GluA1 causation and selective vulnerability remain unisolated** JTX tests Ca2+-permeable AMPAR involvement rather than GluA1 specifically. The abstract also claims selective vulnerability without a cortical excitotoxicity comparison, extending beyond the receptor measurements in one cortical patient line.
  - Dimension: methodological rigour
  - Location: Abstract; Figure 6; Results, cortical-neuron comparison; Discussion
- **Inferential units remain unclear across key assays** Figure 6 distinguishes recorded cells from differentiations but does not state which enters the ANOVA. Uncorrected Fisher's LSD in expression and cytotoxicity analyses adds uncertainty across the multi-line comparisons.
  - Dimension: methodological rigour
  - Location: Figures 5a and 6b,d,f; Methods, Data analysis
- **Tissue confirmation lacks reported blinded outcome scoring** Manual transcript counting uses two independent neuropathologists, but blinded assessment is not reported. The comparison includes only three patients and three controls, limiting precision.
  - Dimension: methodological rigour
  - Location: Figure 7; Methods, Human post-mortem tissue analysis

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity: "Significant p-values for GluA1 C9-1 vs. Con-1: 0.0039" (Fig. 5 legend) vs "C9-3 vs. Con-1: 0.0503" (Fig. 5 legend). The C9-3 versus Con-1 value listed under significant GluA1 comparisons is 0.0503, which exceeds the stated 0.05 threshold. → Conclusion holds
- **Reporting and transparency:** Noted. The Results name RNAscope whereas the tissue Methods name BaseScope reagents. This is a reporting clarification rather than an established problem with the underlying measurements.
  - Ethics approval: declared · Data availability: declared
- **Reference integrity:** Noted. 72 of 74 checkable references verified
  - 74 references in manuscript
  - Could not be verified automatically — queued for manual review:
    - Rothstein, J. D. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv. Neurol. 68, 7–20, discussion 21–27 (1995). (Ambiguous: title ratio 0.51 via crossref_bibliographic sits between the divergence (0.30) and match (0.70) thresholds; too close to call either way, so it is recorded as unresolved rather than judged.)
    - Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalinfixed, paraffin-embedded tissues. J. Mol. Diagn. 14, 22–29 (2012). (Ambiguous: title ratio 0.68 via crossref_bibliographic sits between the divergence (0.30) and match (0.70) thresholds; too close to call either way, so it is recorded as unresolved rather than judged.)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-16
